ViaNautis Bio develops polyNaut®, a non-viral, targeted polymer-based nanovesicle delivery platform for genetic medicines and cell and gene therapies
ViaNautis Bio develops polyNaut®, a non-viral, targeted polymer-based nanovesicle delivery platform for genetic medicines and cell and gene therapies. Its platform is designed for cell-specific delivery to the central nervous system, lungs, and immune system, with flexible payloads, good tolerability, and scalable manufacturing. Applications include oligonucleotide delivery, in vivo CAR-T therapies, and regenerative therapies.